United States Drug Patent 10,512,613: Claim Scope, Expiration, Orange Book Status, and Methylphenidate Patent Landscape
United States Patent No. 10,512,613 protects methods of treating ADHD with a once-daily oral methylphenidate hydrochloride formulation designed to provide approximately 16 hours of efficacy. Its claims combine four technical requirements: an immediate-release and controlled/delayed-release methylphenidate system, specified dose strengths, fed- or fasted-state pharmacokinetic parameters, and a defined dissolution profile.
The patent is directed primarily to the formulation architecture associated with extended-duration methylphenidate bead products, including the 80:20 controlled-release-to-immediate-release drug ratio and layered bead construction. A competing product or generic would face the greatest risk if it uses the same dual-release bead design and produces the claimed pharmacokinetic and dissolution results.
What does US Patent 10,512,613 protect?
Patent 10,512,613 protects a treatment method rather than a composition claim in isolation. Each independent claim requires administration to an ADHD patient of an oral solid pharmaceutical composition containing:
| Requirement |
Claim 1 |
Claim 16 |
| Therapeutic use |
ADHD treatment |
ADHD treatment |
| Active ingredient |
Methylphenidate hydrochloride |
Methylphenidate hydrochloride |
| Release components |
Immediate release plus controlled/delayed release |
Immediate release plus controlled/delayed release |
| Dose strengths |
25, 35, 45, 55, 70, 85, or 100 mg |
Same |
| Pharmacokinetic condition |
Fed state |
Fasted state |
| Duration of efficacy |
16 hours after one administration |
16 hours after one administration |
| Dissolution condition |
Defined USP paddle profile |
Defined USP paddle profile |
| Primary formulation limitation |
Dual-release formulation meeting PK and dissolution requirements |
Same |
The patent therefore has a hybrid claim structure. It does not rely solely on a structural formulation description. It also requires in vivo pharmacokinetic performance and in vitro dissolution behavior.
What are the independent claims in Patent 10,512,613?
Claims 1 and 16 are the two independent claims.
Claim 1 covers administration in a fed state. Claim 16 covers administration in a fasted state. The dependent claims following each independent claim are substantially parallel.
The independent claims require at least two of eight listed pharmacokinetic parameters. The parameters include:
- AUC0-4
- AUC8-12
- AUC12-16
- AUC0-16
- AUC0-12
- AUC12-t
- Cmax0-4
- Cmax8-16
The values are specified at the 100 mg dose. The claims then extend those values to the 25 mg through 85 mg strengths through dose-proportional AUC or Cmax values.
This drafting approach makes the PK limitations central to infringement. A formulation that has the same bead structure but does not meet at least two claimed PK parameters may avoid literal infringement of the independent method claims, subject to doctrine-of-equivalents analysis.
How is the methylphenidate formulation constructed?
Claims 2 through 15 and 17 through 30 progressively narrow the formulation to a coated-bead system.
The claimed bead has the following architecture:
- A core containing delayed- or controlled-release methylphenidate.
- An inner controlled-release coating.
- An outer delayed-release coating.
- An immediate-release methylphenidate layer coated over the outer coating.
The claims permit either a coated granule or a granule substrate in admixture with methylphenidate. Claim 6 narrows the construction to a granule coated with methylphenidate.
The listed granule substrates include:
- Sugar spheres
- Microcrystalline cellulose
- Silica
- Starch
- Lactose
- Calcium carbonate
- Mannitol-polyvinylpyrrolidone granules
The claims identify two coating polymers:
| Layer |
Claimed material |
| Inner controlled-release coating |
Ammonio methacrylate copolymer, Type B USP/NF |
| Outer delayed-release coating |
Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 |
The coating-weight limitations are also material. The broad dependent claims specify:
- Inner controlled-release coating: approximately 3% to 16% by weight of each bead
- Outer delayed-release coating: approximately 3% to 20% by weight of each bead
The narrower claims specify:
- Inner coating: approximately 10.0% to 10.7%
- Outer coating: approximately 15% to 16%
What dose ratio does Patent 10,512,613 require?
Claims 9, 10, 24, and 25 require the controlled/delayed-release component to represent approximately 78% to 82% of the methylphenidate hydrochloride dose. The preferred limitation is approximately 80% controlled/delayed release and 20% immediate release.
The claimed dose allocation is:
| Total methylphenidate HCl |
Controlled/delayed release at 80% |
Immediate release at 20% |
| 25 mg |
20 mg |
5 mg |
| 35 mg |
28 mg |
7 mg |
| 45 mg |
36 mg |
9 mg |
| 55 mg |
44 mg |
11 mg |
| 70 mg |
56 mg |
14 mg |
| 85 mg |
68 mg |
17 mg |
| 100 mg |
80 mg |
20 mg |
A product using a materially different release ratio, such as 50:50 or 70:30, would have a stronger non-infringement position against the narrow dependent claims. It could still face risk under the independent claims if it meets the broader dual-release, PK, efficacy, and dissolution limitations.
What dissolution profile is required?
Both independent claims require the following in vitro dissolution profile:
| Time |
Methylphenidate dissolved |
| 1 hour |
Not less than 15% |
| 4 hours |
18% to 38% |
| 8 hours |
35% to 55% |
| 12 hours |
68% to 98% |
| 16 hours |
Not less than 68% |
The testing method uses:
- USP paddle apparatus
- 100 rpm
- 37°C
- 900 mL medium
- Simulated gastric fluid for two hours
- Phosphate buffer at pH 6.0 for hours three through six
- Phosphate buffer at pH 7.4 from hour seven onward
- USP <711> Acceptance Table 2
The profile is designed to capture a formulation with limited early release, continuing release through the middle interval, and substantial release by 12 to 16 hours.
Because the claim specifies test conditions, infringement testing would require close replication of the claimed method. Changes in apparatus, media volume, pH transition, agitation rate, or sampling intervals could affect comparability and litigation outcomes.
How strong is the patent estate for the claimed formulation?
The patent has meaningful formulation coverage but narrower practical breadth than its independent claims initially suggest.
Strengths
The patent combines multiple performance screens:
- Patient treatment for ADHD
- One-dose, 16-hour efficacy
- Fed- or fasted-state PK
- At least two specified PK parameters
- Dose strengths from 25 mg through 100 mg
- A detailed dissolution profile
A competitor would have difficulty designing around the patent while preserving the same release objective if it also uses an 80:20 layered bead system.
The dependent claims further protect a commercially realistic formulation design, including the ammonio methacrylate controlled-release layer, methacrylate delayed-release layer, coating percentages, and drug layering sequence.
Limitations
The claims are method claims. They do not independently prohibit making or selling every methylphenidate formulation with the same structural features. A patent owner would ordinarily need to establish that the accused product is administered for ADHD treatment and meets the claimed performance limitations.
The PK limitations may create proof burdens. PK values are population averages with standard deviations. The claim language also permits selection of any two of eight parameters. A generic sponsor could challenge whether its product meets the required values, whether the values are dose proportional, and whether the comparison study uses the same fed or fasted conditions.
The “16 hours” efficacy limitation also creates a clinical proof issue. Dissolution similarity alone would not necessarily establish 16-hour clinical efficacy.
When does Patent 10,512,613 lose exclusivity?
Patent 10,512,613 was issued on December 24, 2019. Its ordinary patent term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable statutory extension [1].
Public patent records identify the patent as a pharmaceutical formulation patent assigned to an entity associated with the development of extended-release methylphenidate products. The effective expiration date must be taken from the USPTO patent record and any applicable Orange Book listing because the issue date alone does not determine patent expiration.
The patent’s expected term is materially later than the 2019 issue date and is likely to extend into the mid-2030s based on the underlying priority and filing history. Patent expiration should be distinguished from FDA regulatory exclusivity and from commercial availability. A patent may remain in force after a product is withdrawn, and a product may lose market exclusivity before the patent expires.
What is the FDA and Orange Book status?
The claim profile corresponds to a long-acting methylphenidate product designed for approximately 16 hours of duration. Adhansia XR, developed by Ironshore Pharmaceuticals, was approved by the FDA in 2019 in multiple strengths of methylphenidate hydrochloride extended-release capsules [2].
The FDA labeling describes a capsule containing immediate-release and extended-release methylphenidate components. The product is administered once daily and is indicated for ADHD in patients age six years and older [2].
The Orange Book is the controlling source for listed patents and regulatory exclusivity associated with an approved drug product [3]. Patent 10,512,613 should be evaluated against:
- The Orange Book product record for the relevant methylphenidate extended-release product
- Any listed formulation or method-of-use patents
- The listed patent-use codes
- The approved labeling protected by each method-of-use patent
- Any subsequent delisting, expiration, or product-status changes
The patent does not create a biologic exclusivity issue. Methylphenidate hydrochloride is a small-molecule active ingredient, and the principal abbreviated pathway is an ANDA, not a biosimilar application.
What Paragraph IV risks exist for generic methylphenidate products?
A generic applicant could file a Paragraph IV certification against a listed patent if it asserts that the patent is invalid, unenforceable, or will not be infringed by the proposed product [4].
Potential Paragraph IV positions against Patent 10,512,613 include:
Non-infringement
A generic applicant could attempt to avoid one or more required limitations by using:
- A different immediate-release-to-controlled-release ratio
- A single controlled-release matrix instead of layered beads
- A different delayed-release polymer
- A different coating weight
- A dissolution profile outside the claimed ranges
- PK results that do not meet at least two claimed parameters
- A dosing regimen or label that does not practice the claimed ADHD method
Invalidity
Potential invalidity theories could focus on:
- Anticipation by an earlier methylphenidate formulation or clinical study
- Obviousness based on known immediate-release and delayed-release combinations
- Written-description support for the specific PK combinations
- Enablement of all listed doses, fed and fasted conditions, and formulation variations
- Definiteness of terms such as “efficacious treatment,” “dose proportional,” and “at least two”
The PK limitations may support patentability if the record shows an unexpected exposure pattern or duration of effect. They may be vulnerable if the values merely reflect routine optimization of a known extended-release formulation.
Which companies compete in long-acting methylphenidate?
The competitive market includes several distinct release technologies:
| Product |
Company or sponsor |
General release concept |
Competitive distinction |
| Adhansia XR |
Ironshore Pharmaceuticals |
Immediate and extended-release methylphenidate beads |
Approximately 16-hour duration |
| Concerta |
Janssen, now associated with Johnson & Johnson |
Osmotic controlled-release tablet |
OROS delivery system |
| Ritalin LA |
Novartis |
Immediate- and delayed-release bead capsules |
Biphasic release |
| Aptensio XR |
Rhodes Pharmaceuticals |
Extended-release multiparticulate formulation |
Long-acting methylphenidate |
| Jornay PM |
Ironshore Pharmaceuticals |
Delayed-release and extended-release methylphenidate |
Evening dosing, morning onset |
| Quillivant XR |
Tris Pharma |
Extended-release oral suspension |
Liquid delivery |
| Quillichew ER |
Tris Pharma |
Extended-release chewable tablet |
Chewable dosage form |
| Daytrana |
Noven Pharmaceuticals |
Transdermal methylphenidate |
Nonoral delivery |
The closest structural comparators are Ritalin LA and other multiparticulate products. Concerta is less likely to practice the layered bead limitations because it uses an osmotic tablet technology. Liquid and transdermal products are also structurally distant, although they compete in the same ADHD treatment market.
What manufacturing and intellectual-property barriers matter?
The formulation may require multiple controlled manufacturing steps:
- Preparation or selection of the inert granule.
- Drug layering with methylphenidate hydrochloride.
- Application of the inner controlled-release coating.
- Application of the outer delayed-release coating.
- Application of the immediate-release methylphenidate layer.
- Encapsulation and dose-strength scaling.
- Dissolution and PK control across seven dose strengths.
The process risk is not limited to the active ingredient. The coating sequence, coating weight, polymer grade, bead uniformity, capsule fill, and release testing all affect whether a product meets the claimed performance profile.
A generic manufacturer could design around the patent with a matrix tablet, osmotic system, liquid formulation, transdermal system, or a multiparticulate system using different release mechanisms. Such designs may still encounter separate patents owned by competing sponsors.
What litigation and settlement issues should be monitored?
The relevant litigation record should be searched by patent number, product name, sponsor, and ANDA applicant. Key events include:
- Paragraph IV notices
- Hatch-Waxman complaints
- Thirty-month stays
- Preliminary injunction motions
- Claim-construction rulings
- ANDA settlements
- Launch-at-risk announcements
- Patent delisting or expiration
No conclusion about a current settlement or active Paragraph IV dispute should be drawn solely from the patent text. The controlling sources are PACER, district court dockets, Federal Circuit opinions, FDA Orange Book updates, and the FDA Paragraph IV patent challenge list.
Key Takeaways
- Patent 10,512,613 covers ADHD treatment using dual-release methylphenidate hydrochloride formulations.
- Claims 1 and 16 distinguish fed-state and fasted-state administration.
- The formulation must meet specified PK performance, 16-hour efficacy, and dissolution requirements.
- Dependent claims target layered coated beads with approximately 80% controlled/delayed-release and 20% immediate-release methylphenidate.
- The narrowest claims identify ammonio methacrylate and methacrylate-based coating systems at specified coating weights.
- The principal generic risk is highest for a multiparticulate product that copies the 80:20 layered-bead architecture.
- A competitor using a matrix tablet, osmotic system, liquid, transdermal system, or materially different bead technology may have stronger design-around arguments.
- Methylphenidate is a small molecule, so biosimilar exclusivity is not relevant.
- Paragraph IV exposure depends on the Orange Book listing, the approved labeling, the asserted patent claims, and the generic product’s actual PK and dissolution data.
- The patent is expected to have a term extending into the mid-2030s, subject to the official USPTO term calculation and any Orange Book status changes.
FAQs
Does Patent 10,512,613 cover all extended-release methylphenidate products?
No. It targets products combining immediate-release and controlled/delayed-release methylphenidate that also meet specified PK, efficacy, and dissolution limitations.
Does the patent require an 80:20 immediate-release-to-extended-release ratio?
The independent claims do not expressly require that ratio. Dependent claims 9, 10, 24, and 25 narrow the formulation to approximately 80% controlled/delayed release and 20% immediate release.
Can a generic avoid the patent by using a different coating polymer?
Potentially. A different polymer may avoid the narrow dependent claims, but the generic must also avoid the independent claims’ PK, dissolution, efficacy, dose, and dual-release requirements.
Is Patent 10,512,613 a composition patent?
The asserted claims supplied here are method-of-treatment claims. The claims protect administering a qualifying oral composition for ADHD treatment rather than simply claiming the composition without a therapeutic-use limitation.
Does withdrawal of a methylphenidate product eliminate patent infringement risk?
No. Product withdrawal may affect commercial exposure and Orange Book status, but it does not automatically invalidate or terminate an issued patent.
References
-
United States Patent and Trademark Office. (2019). U.S. Patent No. 10,512,613. Washington, DC: U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2019). Adhansia XR prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.). ANDA submissions: Patent certification and notification under the Hatch-Waxman Amendments. Silver Spring, MD: U.S. Department of Health and Human Services.
